What does license — upfront payment mean?

The initial, non-refundable cash payment received from a partner upon the execution of a licensing or collaboration agreement. This payment represents the immediate value recognized for granting access to intellectual property or research assets before clinical or commercial milestones are achieved.

Praxis Precision Medicines, Inc. PRAX License — Upfront payment

Similar metrics at other companies

IONSUpfront Royalty Payment Received

$500M—

HALOUpfront license and target nomination fees — Revenue from Contract with Customer, Excluding Assessed Tax

$0-100%

ORKANon Refundable License Fee

$150K—

JAN

JANPrepaid Licensing

$1.41M—

SNPSLicense — Total Revenue

$546.25M+7.0%

ERASPhase2Clinical Trial — Payment For Option To Expand Territory Of License On Or Prior To First Dosing Of First Patient

$50M—

Other financials

Income statement

See full

Revenue--100%

Operating income-$105.9M-41.7%

Net income-$92.6M-33.6%

EPS (diluted)-$3.20+2.7%

Balance sheet

See full

Cash & equivalents$536.7M+223%

Total debt$1.4M+31.3%

Total equity$1.4B+221%

Total assets$1.5B+205%

Cash flow

See full

Operating cash flow-$86.2M-62.5%

CapEx$62.0K—

Free cash flow-$86.2M-62.6%

Valuation

See full

Market cap$8.51B+1,075%

Profitability

See full

Operating margin-3,927.5%-1,497pp

Net margin-3,658.5%-1,388pp

FCF margin-3,067.4%-1,030pp

Returns & leverage

See full

Return on equity-35.3%-10.9pp

Debt / equity0×0.0×

Current ratio15.9×+7.4×

Where this comes from

Reported directly by Praxis Precision Medicines, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiability.

The official record: Praxis Precision Medicines, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Praxis Precision Medicines, Inc.'s license — upfront payment.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Praxis Precision Medicines, Inc.'s license — upfront payment?: Praxis Precision Medicines, Inc. (PRAX) reported license — upfront payment of $0 in Q1 2026.
What does license — upfront payment mean?: The initial, non-refundable cash payment received from a partner upon the execution of a licensing or collaboration agreement. This payment represents the immediate value recognized for granting access to intellectual property or research assets before clinical or commercial milestones are achieved.